AMGN · AMGEN Inc
United States · RS rating 95 · As of 2026-11-03
| Price | 461.26 USD |
|---|---|
| 1-day change | -0.9% |
| RS rating (overall / 1M / 3M / 12M) | 95 / 89 / 85 / 87 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 51 / 77 / 58 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -58.7% |
| Sales growth Q/Q | +3.2% |
| Distance from 52-week high | +1.0% |
| Market cap (USD) | $187.9B |